- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Idiopathic pulmonary fibrosis (IPF) Progressive fibrosing Interstitial lung disease (PF-ILD)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 564KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 1.6MB)
Nintedanib – November 2024
Nintedanib; Capsule 100 mg, Capsule 150 mg, Ofev®
Last updated
30 May 2025